Medicare Payments For Sensipar, Parsabiv Could Be Bellwether For Dialysis Drug Developers

Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside  Medicare's reimbursement bundle for end-stage renal disease.